Abstract
In 1990s, it was found that GSAD is more common, more disabling, and more chronic than previously realized. For the first time, there are good data about a range of effective treatment options that can offer these patients substantial relief and protection from their disability.
MeSH terms
-
Anti-Anxiety Agents / therapeutic use
-
Behavior Therapy
-
Benzodiazepines
-
Chronic Disease
-
Combined Modality Therapy
-
Comorbidity
-
Diagnosis, Differential
-
Humans
-
Interview, Psychological
-
Mass Screening / methods
-
Models, Psychological
-
Phobic Disorders / classification
-
Phobic Disorders / diagnosis*
-
Phobic Disorders / epidemiology
-
Phobic Disorders / etiology
-
Phobic Disorders / therapy*
-
Prevalence
-
Psychiatric Status Rating Scales
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
United States / epidemiology
Substances
-
Anti-Anxiety Agents
-
Serotonin Uptake Inhibitors
-
Benzodiazepines